Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Healthy Participants 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Solid Tumor, Adult 2Healthy Volunteers 2Breast Neoplasms 2cMET-dysregulated Advanced Solid Tumors 1TP53 Y220C Mutation 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Healthy Adult Participants 1Healthy 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Chronic Cough 1Carcinoma, Squamous Cell 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Non-small Cell Lung Cancer 1

Interventions

enzalutamide 4darolutamide 2xentuzumab 1olaparib 1ipatasertib 1ibrutinib 1gallium 68 PSMA-11 1atezolizumab 1apalutamide 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Docetaxel 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms, Castration-Resistant × Rosuvastatin Calcium × Clear all
NCT02592317 2026-05-08

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 1 Active not recruiting
23 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡